Clinical trial
Staccato Loxapine in Agitation (Proof of Concept)
NCT00369577 · Alexza Pharmaceuticals, Inc., Other · Completed
Key facts
| NCT number | NCT00369577 |
|---|---|
| Title | Staccato Loxapine in Agitation (Proof of Concept) |
| Official title | A Multi-center, Randomized, Double-blind, Placebo-controlled, Single Dose Efficacy and Safety Study of StaccatoTM Loxapine for Inhalation in Schizophrenic Patients With Agitation. |
| Lead sponsor | Alexza Pharmaceuticals, Inc., Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Inhaled Placebo, Inhaled Loxapine 5 mg, Inhaled Loxapine 10 mg |
| Enrollment | 129 |
| Start date | Aug 1, 2006 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2007 |
| First posted | Aug 29, 2006 |
| Last update posted | Jan 2, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: